Form 4: Vaxcyte SVP, Finance, Elvia Cowan, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., exercised stock options and sold 5,000 shares of common stock at $85 per share on July 16, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 16, 2024, Elvia Cowan, the SVP of Finance at Vaxcyte, Inc. (PCVX), exercised a stock option to purchase 5,000 shares of common stock at a price of $25.92 per share.
• Simultaneously, Cowan sold 5,000 shares of Vaxcyte common stock at $85 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2023.
• Following these transactions, Cowan directly owns 12,723 shares of Vaxcyte common stock and holds options for 119,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine transaction under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider transactions are common, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on non-public information. The market will likely view this as a routine transaction.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options as a significant component.
• Rule 10b5-1 trading plans are a standard practice for executives to manage their stock holdings and avoid insider trading accusations.
• The vesting schedule of the options (1/4 vesting initially, then monthly) is a typical arrangement to incentivize long-term employment.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders as it is a routine sale under a pre-arranged plan.

Key Dates